CN101780266A - 防治畜禽呼吸道疾病的复方制剂 - Google Patents
防治畜禽呼吸道疾病的复方制剂 Download PDFInfo
- Publication number
- CN101780266A CN101780266A CN201010131382A CN201010131382A CN101780266A CN 101780266 A CN101780266 A CN 101780266A CN 201010131382 A CN201010131382 A CN 201010131382A CN 201010131382 A CN201010131382 A CN 201010131382A CN 101780266 A CN101780266 A CN 101780266A
- Authority
- CN
- China
- Prior art keywords
- grams
- livestock
- compound preparation
- poultry
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000144972 livestock Species 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 208000023504 respiratory system disease Diseases 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 title claims abstract description 17
- 244000144977 poultry Species 0.000 title abstract description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 12
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 12
- 239000011734 sodium Substances 0.000 claims abstract description 12
- 241000241413 Propolis Species 0.000 claims abstract description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 11
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 claims abstract description 11
- 229960002129 cefixime Drugs 0.000 claims abstract description 11
- 229960001031 glucose Drugs 0.000 claims abstract description 11
- 229940069949 propolis Drugs 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 10
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims abstract description 10
- 229960001225 rifampicin Drugs 0.000 claims abstract description 10
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims abstract description 9
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960001380 cimetidine Drugs 0.000 claims abstract description 9
- 229960004082 doxycycline hydrochloride Drugs 0.000 claims abstract description 9
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims abstract description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 4
- 239000008103 glucose Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 9
- 229960004260 indomethacin sodium Drugs 0.000 claims description 8
- JMHRGKDWGWORNU-UHFFFAOYSA-M sodium;2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound [Na+].CC1=C(CC([O-])=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 JMHRGKDWGWORNU-UHFFFAOYSA-M 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 7
- 210000004877 mucosa Anatomy 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 230000003115 biocidal effect Effects 0.000 abstract description 3
- 230000008439 repair process Effects 0.000 abstract description 3
- 230000000241 respiratory effect Effects 0.000 abstract description 3
- 239000003443 antiviral agent Substances 0.000 abstract description 2
- 230000000091 immunopotentiator Effects 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 description 13
- 241000271566 Aves Species 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000002994 raw material Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000192125 Firmicutes Species 0.000 description 4
- 229930186147 Cephalosporin Natural products 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- UPLPHRJJTCUQAY-WIRWPRASSA-N 2,3-thioepoxy madol Chemical compound C([C@@H]1CC2)[C@@H]3S[C@@H]3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 UPLPHRJJTCUQAY-WIRWPRASSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- 241000606069 Chlamydiaceae Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010070814 Corrosive gastritis Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 108010079943 Pentagastrin Proteins 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003323 beak Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001595 lincomycin hydrochloride Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229940124588 oral cephalosporin Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
- 229960000444 pentagastrin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229960002109 tuberculosis vaccine Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种防治畜禽呼吸道疾病的复方制剂，其特征在于：按100g为单位重量由以下组分混合均匀制成：头孢克肟钠2-5g、盐酸多西环素10-30g、利福平5-10g、西咪替丁5-20g、吲哚美辛钠2-10g、蜂胶粉2-6g、胞壁酰二肽2-6g、余量为药学上适用的辅料。所述药学上适用的辅料为无水葡萄糖或口服葡萄糖，优选为无水葡萄糖。本发明采用抗生素药、抗病毒药、免疫增强剂及粘膜修复因子复配成复方制剂，对畜禽呼吸道症状有高效快速治疗作用。其制备简单，效果显著，应用广泛。
Description
技术领域
本发明涉及一种防治畜禽疾病的复方制剂，特别涉及一种防治畜禽呼吸道疾病的复方制剂。
背景技术
目前，随着饲养业的快速发展，疾病也随之肆虐，特别是呼吸系统疾病，发病越来越多；同时由于抗生素类药物在饲养业方面的滥用，耐药菌株的不断产生，使得畜禽呼吸系统疾病的治疗越来越困难。该病引起饲养动物的死亡增加、生长减缓、料肉比增加，以及加大药物、疫苗和人工费用支出等，给饲养户带来相当严重的损失。畜禽的呼吸道疾病病原复杂，易引起多种疾病的继发感染。临床表现流泪、流鼻涕、咳嗽或打喷嚏、喘气、呼吸困难等症状。现有的治疗畜禽呼吸道疾病的药物往往以抗菌作用的西药为主，虽然可取得一定的疗效，但对病毒引起的疾病却无作用。
因此，提供一种防治畜禽呼吸道疾病的复方制剂，即成为该领域技术人员急待着手解决的问题之一。
发明内容
本发明的目的在于克服上述不足之处，提供一种高效、速效、标本兼治的防治畜禽呼吸道疾病的复方制剂。
为实现上述目的本发明所采用的技术方案是：一种防治畜禽呼吸道疾病的复方制剂，其特征在于：按100g为单位重量由以下组分混合均匀制成：头孢克肟钠2-5g、盐酸多西环素10-30g、利福平5-10g、西咪替丁5-20g、吲哚美辛钠2-10g、蜂胶粉2-6g、胞壁酰二肽2-6g、余量为药学上适用的辅料。
按100g为单位重量由以下较佳含量组分混合均匀制成：头孢克肟钠3g、盐酸多西环素20g、利福平10g、西咪替丁15g、吲哚美辛钠8g、蜂胶粉3g、胞壁酰二肽3g、余量为药学上适用的辅料。
所述药学上适用的辅料为无水葡萄糖或口服葡萄糖。
本发明各种药物的特性及组方原理：
头孢克肟钠：对革兰氏阳性菌和阴性菌具有广谱抗菌作用，特别是对革兰氏阳性菌中的链球菌属、肺炎球菌及革兰氏阴性菌等显示出比其它口服头孢菌素类更强的杀菌作用；通过抑制细菌细胞壁合成而起杀菌作用，对各种细菌产生的β-内酰胺酶极其稳定，能有效地抑制或杀灭临床上对其它头孢类抗生素产生耐药性的肠杆菌、沙雷氏菌以及变形杆菌等；头孢克肟钠是迄今为止所有临床使用的头孢抗生素中使用剂量最小的药品，仅为其它头孢类抗生素的1/10至1/5，并在体内有持久的有效杀菌浓度；头孢克肟钠有着良好的渗透性，很容易穿过屏障，可用于畜禽的重症全身细菌感染。
盐酸多西环素：又称强力霉素，属于四环素类抗生素。本品为广谱抑菌剂，高浓度时具杀菌作用。许多立克次体属、支原体属、衣原体属、非典型分枝杆菌属、螺旋体也对本品敏感。本品对革兰氏阳性菌作用优于革兰氏阴性菌，但肠球菌属对其耐药。本品作用机制为药物能特异性与细菌核糖体30S亚基的A位置结合，抑制肽链的增长和影响细菌蛋白质的合成。
利福平：利福平为利福霉素类半合成广谱抗菌药，对多种病原微生物均有抗菌活性。该药对结核分枝杆菌和部分非结核分枝杆菌（包括麻风分枝杆菌等）在宿主细胞内外均有明显的杀菌作用；对需氧革兰阳性菌具良好抗菌作用，包括葡萄球菌产酶株及甲氧西林耐药株、肺炎链球菌、其它链球菌属、肠球菌属、李斯特菌属、炭疽杆菌、产气荚膜杆菌、白喉杆菌、厌氧球菌等；对需氧革兰阴性菌如脑膜炎奈瑟球菌、流感嗜血杆菌、淋病奈瑟球菌亦具高度抗菌活性。其抗菌机理是与70s核蛋白体的50s亚基上的a位紧密结合，阻碍了肽酰基转移酶的转肽反应，使肽链不能延伸，而抑制细菌蛋白质的合成。
西咪替丁：为一种H2受体拮抗剂，能明显地抑制食物、组胺、五肽胃泌素、咖啡因与胰岛素等刺激引起的胃酸分泌。本品对因化学刺激引起的腐蚀性胃炎具有预防和保护作用，并且具有较强的粘膜修复作用，从而起到保护粘膜免疫的功能。本品有抗病毒作用，能刺激诱发病毒抑制因子的产生，提高宿主细胞免疫功能，增强机体细胞的免疫功能，在病毒感染的各个阶段都能发挥一定的作用，促使病毒感染过程迅速恢复，而达到抗病毒作用。
吲哚美辛钠：是一种非甾体解热镇痛药物，具有显著的解热、消炎、镇痛、止泻和增加抗菌药物组织血药浓度的特点，作用机理是减少前列腺素的合成，减轻炎症反应。
蜂胶粉：蜂胶是蜜蜂从植物花苞及树干上采集的树胶，混入其上颚腺分泌物和蜂蜡等物质而成的一种具有芳香气味的胶状固体物质。蜂胶的化学成分复杂，具有抗病毒、抗细菌、抗真菌、抗肿瘤、抗氧化、防辐射、促进组织再生以及增强免疫力等多种功能，它是一种天然的广谱抗菌剂，可治疗多种畜禽疾病。
胞壁酰二肽：本品是结核分枝杆菌细胞壁上仍保有结核菌苗佐剂作用的最小活性组分，具有强大的激活机体各个脏器的功能；可增强抗原的免疫原活性，刺激巨噬细胞，促进淋巴因子释放，促进B淋巴细胞和T淋巴细胞的功能；能够快速修复受损黏膜，促进营养物质的吸收，提高营养物质的吸收速度和肠道绒毛的长度的密度，维持肠道的良好内环境，并增强机体的抗病能力，恢复生产机能。
本发明的有益效果是：本发明是在对抗菌药物的配伍活性进行大量研究的基础上提出的。通过立体组方，把诸多的感染原因都考虑周密，不让一种病原微生物漏网；把致命的原因考虑全面，消炎、杀菌、抗病毒、抑制支原体、提升免疫力、修复黏膜、控制继发感染等。本发明采用各种市售的抗生素药、抗病毒药、免疫增强剂及粘膜修复因子复配成复方制剂，对畜禽呼吸道症状有高效治疗作用。其制备简单，效果显著，应用广泛。
具体实施方式
以下结合较佳实施例，对依据本发明提供的具体实施方式详述如下：
实施例1
按照如下配比分别称取原料：头孢克肟钠3g、盐酸多西环素20g、利福平10g、西咪替丁15g、吲哚美辛钠8g、蜂胶粉3g、胞壁酰二肽3g，加无水葡萄糖或口服葡萄糖至100g；混合均匀，即制成一种具有特效的防治畜禽呼吸道疾病的复方制剂。所述原料均为市售产品。
实施例2
按照如下配比分别称取原料：头孢克肟钠5g、盐酸多西环素15g、利福平10g、西咪替丁7g、吲哚美辛钠3g、蜂胶粉2g、胞壁酰二肽5g，加无水葡萄糖至100g，混合均匀；即制成一种具有特效的防治畜禽呼吸道疾病的复方制剂。所述原料均为市售产品。
实施例3
按照如下配比分别称取原料：头孢克肟钠2g、盐酸多西环素25g、利福平6g、西咪替丁18g、吲哚美辛钠8g、蜂胶粉5g、胞壁酰二肽2g，加无水葡萄糖至100g，混合均匀；即制成一种具有特效的防治畜禽呼吸道疾病的复方制剂。所述原料均为市售产品。
临床应用：
一、发病情况
某养殖鸡群于去年7月上旬出现普遍拉稀现象，用盐酸林可霉素可溶性粉治疗5天后全群恢复正常。可鸡群于9月18日又出现呼吸道疾病症状，用红霉素、病毒唑等原料药治疗无效，而且每天死亡鸡只达20只左右，9月23日死亡鸡只达50余只。
二、临床症状
全鸡群出现明显的呼吸道疾病症状，伸颈呼吸，气喘，甩头，采食下降，精神沉郁，喙缘流涎，鼻孔上有料渣杜塞，拉黄绿、灰绿色稀粪，跛行，死亡鸡只全身呈紫红色。
三、病理变化
（1）咽喉充血、出血，气管内有灰白色混浊黏液，气管环充血，眼睛内有泡状的液体，眼结膜充血，有干酪样渗出物。
（2）腺胃黏液呈灰白色，部分鸡的胰腺充血，腹腔内有灰白色或灰黄色的含泡沫的液体，肠道淋巴结滤泡出血、肿胀。
（3）鸡的肝脏肿大，脾脏微肿，肾脏有轻微的充血现象。
四、防治措施
隔离发病鸡只，对其单独饲养，投药治疗；将病死鸡的尸体在远离鸡场的地方深埋；对全鸡场内的相关设施进行彻底消毒。
五、药物治疗
发病鸡只9月24日开始使用本发明产品，每100g兑水100kg，或每100g拌料50-100kg；从第二日死亡只数降低，到第三天不再发生死亡，连用4-5日后饮食恢复到正常水平。
上述参照实施例对防治畜禽呼吸道疾病的复方制剂所进行的描述，是说明性的而不是限定性的，可按照所限定范围列举若干个实施例，因此在不脱离本发明总体构思下的变化和修改，应属于本发明的保护范围之内。
Claims (3)
1.一种防治畜禽呼吸道疾病的复方制剂，其特征在于：按100g为单位重量由以下组分混合均匀制成：头孢克肟钠2-5g、盐酸多西环素10-30g、利福平5-10g、西咪替丁5-20g、吲哚美辛钠2-10g、蜂胶粉2-6g、胞壁酰二肽2-6g、余量为药学上适用的辅料。
2.根据权利要求1所述的防治畜禽呼吸道疾病的复方制剂，其特征在于：按100g为单位重量由以下较佳含量组分混合均匀制成：头孢克肟钠3g、盐酸多西环素20g、利福平10g、西咪替丁15g、吲哚美辛钠8g、蜂胶粉3g、胞壁酰二肽3g、余量为药学上适用的辅料。
3.根据权利要求1或2所述的防治畜禽呼吸道疾病的复方制剂，其特征在于：所述药学上适用的辅料为无水葡萄糖或口服葡萄糖。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010131382A CN101780266A (zh) | 2010-03-24 | 2010-03-24 | 防治畜禽呼吸道疾病的复方制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010131382A CN101780266A (zh) | 2010-03-24 | 2010-03-24 | 防治畜禽呼吸道疾病的复方制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101780266A true CN101780266A (zh) | 2010-07-21 |
Family
ID=42520490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010131382A Pending CN101780266A (zh) | 2010-03-24 | 2010-03-24 | 防治畜禽呼吸道疾病的复方制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101780266A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872014A (zh) * | 2012-08-03 | 2013-01-16 | 九江大成制药有限公司 | 一种复方氟苯尼考组合物及其制备工艺和应用 |
| CN103110929A (zh) * | 2012-12-10 | 2013-05-22 | 江苏开元医药化工有限公司 | 米屈肼和赖诺普利的药物组合物及其制备方法 |
| CN105641548A (zh) * | 2016-01-22 | 2016-06-08 | 江西傲新生物科技有限公司 | 一种防治和净化猪蓝耳病的药物组合物、制备方法及其应用 |
-
2010
- 2010-03-24 CN CN201010131382A patent/CN101780266A/zh active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872014A (zh) * | 2012-08-03 | 2013-01-16 | 九江大成制药有限公司 | 一种复方氟苯尼考组合物及其制备工艺和应用 |
| CN102872014B (zh) * | 2012-08-03 | 2015-08-19 | 九江大成制药有限公司 | 一种复方氟苯尼考组合物及其制备工艺和应用 |
| CN103110929A (zh) * | 2012-12-10 | 2013-05-22 | 江苏开元医药化工有限公司 | 米屈肼和赖诺普利的药物组合物及其制备方法 |
| CN105641548A (zh) * | 2016-01-22 | 2016-06-08 | 江西傲新生物科技有限公司 | 一种防治和净化猪蓝耳病的药物组合物、制备方法及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1469711A (zh) | 用异硫氰酸酯治疗螺杆菌 | |
| CN102697784B (zh) | 一种兽用恩诺沙星注射液及其制备方法 | |
| EP2415475B1 (en) | Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum | |
| KR100333113B1 (ko) | 헬리코박터피롤리관련위십이지장질환의치료방법 | |
| CN102727531A (zh) | 一种对阴道炎具有治疗和预防作用的活性乳酸菌胶囊 | |
| CN109985069B (zh) | 益生菌组合物及其用途 | |
| CN110859845A (zh) | 丹参酮类化合物的应用 | |
| KR101373770B1 (ko) | 백지 추출물을 유효성분으로 함유하는 장출혈성 대장균 감염증의 예방 또는 치료용 약학 조성물 | |
| CN101780266A (zh) | 防治畜禽呼吸道疾病的复方制剂 | |
| US6242424B1 (en) | Moenomycin and its derivatives for the production of pharmaceuticals, and pharmaceuticals containing moenomycin or its derivatives | |
| CN101780270A (zh) | 用于治疗禽呼吸道疾病的复方可溶性粉 | |
| JP2018501294A (ja) | タウリンのコロナウイルス属及び／又はロタウイルス属のウィルスにより引き起こされる疾患の予防及び／又は治療における応用 | |
| CN111544451A (zh) | 用于抗幽门螺杆菌的组合物及其应用 | |
| Islam | Single dose tetracycline in cholera. | |
| KR101348177B1 (ko) | 패장 추출물을 유효성분으로 함유하는 장출혈성 대장균 감염증의 예방 또는 치료용 약학 조성물 | |
| CN103153304B (zh) | 用于治疗幽门螺旋杆菌感染的组合物 | |
| CN108670951A (zh) | 一种兽用硫酸庆大霉素-盐酸林可霉素复方缓释注射液及其制备方法 | |
| CN116121136A (zh) | 一种缓解便秘的益生菌组合物及其应用 | |
| WO2023049162A1 (en) | Antimicrobial peptides | |
| CN101797374A (zh) | 用于治疗禽类呼吸系统疾病的复方盐酸米诺环素可溶性粉 | |
| CN109420164B (zh) | 阿莫西林菠萝蛋白酶组合物及其制备方法和用途 | |
| CN115551503B (zh) | 使用替莫西林管理微生物失调 | |
| Borisenko et al. | The efficacy tests results of the veterinary drug" trifuzol 1% solution for injection" | |
| CN115006496B (zh) | 一种治疗狐貉貂肺炎的中草药组合物 | |
| JP2002265354A (ja) | 抗ピロリ菌剤組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100721 |